Can DSC, TGA, XRPD, and KF Confirm Solvates and Hydrates in Organic Intermediates?

July 24, 2026

Elena Duan

Summary

Can an organic intermediate be approved as the intended hydrate, solvate, or anhydrous form because its Karl Fischer result, TGA mass loss, DSC curve, and XRPD pattern all appear acceptable?

Not automatically.

The approval question is not whether four analytical files are present. It is whether the results support one consistent explanation of the material delivered:

which volatile component is present;
whether it is part of the solid structure or only physically retained;
whether its removal changes the crystalline phase;
whether the evaluated sample represents the material that will be used in pilot and commercial production.

KF measures water under a defined procedure. TGA measures mass change. DSC records thermal events. XRPD evaluates crystalline-phase characteristics. Each method answers a different part of the problem, and none can independently prove the identity, quantity, physical state, and commercial consistency of a hydrate or solvate.

For form-sensitive organic chemical intermediates, approval should depend on whether the four results can be reconciled, not whether each result is individually marked as conforming.

What Each Test Can Support—and What It Cannot Prove

Karl Fischer Measures Water, Not Hydrate Identity

Karl Fischer testing can determine the water measured under the selected sample preparation and test conditions. It does not independently distinguish among:

water incorporated into a crystalline hydrate;
surface-adsorbed moisture;
water retained in an amorphous fraction;
water introduced during sampling;
incompletely extracted water;
water associated with another component in the sample.

A KF result may be consistent with a proposed hydrate, but numerical agreement with a theoretical water fraction does not prove that the water occupies a defined lattice position.

The reviewer still needs to know whether the sample released its water adequately during testing and whether the crystalline phase agrees with the proposed hydrate.

TGA Measures Mass Loss, Not Volatile Identity

TGA can show:

when mass loss begins;
whether the loss occurs in one or several stages;
how much mass is lost over a defined temperature region;
whether loss continues into a region associated with thermal degradation.

It cannot identify the lost component by mass change alone.

An early mass-loss step could include water, an organic solvent, several volatile components, or the beginning of decomposition. A value close to the theoretical loss of a proposed hydrate or solvate is supporting evidence, not final identification.

TGA also cannot determine whether the lost material was structurally incorporated into the crystal or physically trapped in particles, pores, or agglomerates.

DSC Shows a Thermal Event, Not Its Chemical Cause

DSC records heat-flow events that may be associated with:

dehydration or desolvation;
melting;
crystallization;
solid-state conversion;
glass transition;
reaction or decomposition.

A broad endotherm before melting is often described as dehydration or desolvation. That assignment is not secure unless corresponding mass loss or other supporting evidence is available.

A DSC event may overlap with melting, phase conversion, or decomposition. Its position and shape can also be affected by heating rate, pan configuration, atmosphere, sample mass, particle condition, and prior humidity exposure.

DSC can strengthen a form assignment when the event is reproducible and agrees with TGA, KF, and XRPD. It should not be used alone to identify or quantify water or solvent.

XRPD Shows Crystalline-Phase Characteristics, Not Water or Solvent Content

XRPD can help determine whether:

a batch matches a defined reference form;
controlled drying produces a different phase;
more than one crystalline phase may be present;
the evaluated sample and a commercial batch have comparable diffraction patterns.

A matching XRPD pattern does not prove that water or residual solvent meets a quantitative requirement.

Routine XRPD may not clearly reveal a small amount of another phase, especially when characteristic peaks overlap or the secondary material is poorly crystalline. Grinding, preferred orientation, particle-size differences, and sample preparation can also affect the pattern.

An XRPD result reported only as “conforms” has limited decision value when the reference pattern, sample treatment, comparison basis, and relevant regions are not defined.

Cross-Checking Conflicting Results

The most useful review does not ask whether the numerical results are identical. It asks whether they support a coherent material-state explanation.

Observed Combination	What It May Support	What Remains Unproven	Approval Implication
KF and early TGA loss are broadly consistent, while XRPD matches a defined hydrate reference	Water probably contributes to the mass loss, and the dominant phase may be consistent with the proposed hydrate	Whether all measured water is lattice-associated and whether the form is consistent across batches	Continue review with sample-history and batch-representativeness checks
TGA loss is materially higher than KF water	A nonaqueous volatile, additional water not recovered by KF, overlapping events, or decomposition may contribute	Identity and physical state of the additional mass loss	Hold the form assignment until component-specific evidence is available
KF varies, but XRPD remains similar	Adsorbed, amorphous, or nonstoichiometric water may be involved	Whether the water variation affects dosing, flow, stability, or downstream processing	Evaluate against the intended application rather than approving by XRPD alone
DSC shows a pre-melting endotherm, but TGA shows little corresponding loss	A solid-state transition, melting-related event, or another thermal process may be present	Whether any volatile component is involved	Do not label the event as dehydration or desolvation without more evidence
XRPD changes after controlled drying	Drying altered the crystalline arrangement	Whether the original or dried form is intended, stable, and commercially reproducible	Define the target form before qualification
XRPD differs between the evaluated sample and the commercial batch, while HPLC purity remains similar	Chemical purity may be comparable despite different solid forms	Whether the phase difference affects handling or process performance	Do not extend sample approval directly to bulk material
TGA and KF appear acceptable, but the claimed form is a nonaqueous solvate	Water and total mass loss may be controlled	Identity and quantity of the organic solvent	Require an appropriate solvent-specific result
All four tests are present but were run on different batches or differently conditioned aliquots	The product has historical analytical data	Whether the results describe one actual batch in one material state	Do not combine the files into a single form conclusion

Why KF and TGA Agreement Is Not Enough

When KF water and TGA mass loss are similar, it is reasonable to infer that water contributes substantially to the observed loss.

It is not yet reasonable to conclude that the sample is a defined hydrate.

A defensible hydrate assignment also needs evidence that the crystalline phase is consistent with the proposed form and that the measured water is not mainly surface moisture or water retained outside the ordered structure.

The sample histories must also be comparable. A KF aliquot exposed to room humidity and an XRPD aliquot tested immediately after opening may not represent the same material condition, even when both came from the same container.

Why TGA Minus KF Is Not Automatically Residual Solvent

A common shortcut is:

TGA mass loss − KF water = organic solvent content

That calculation is only a hypothesis.

The difference may include:

an organic solvent;
several volatile components;
water not recovered by the KF procedure;
loss associated with overlapping thermal events;
early degradation products;
differences between the aliquots used for each test.

The identity and amount of a nonaqueous solvent require a method capable of measuring that component. Mathematical subtraction does not convert an unidentified mass loss into a confirmed solvent result.

Why an Unchanged XRPD Pattern Does Not Make Water Variation Irrelevant

If KF water changes while XRPD remains similar, the additional water may not have produced a clearly detectable crystalline-phase change.

That does not mean the variation has no quality impact.

Water outside a defined hydrate phase may still affect:

as-is assay;
reaction equivalents;
hydrolysis-sensitive chemistry;
powder flow and agglomeration;
drying time;
storage behavior;
batch-to-batch process reproducibility.

The relevant decision is whether the water variation changes the way the material is weighed, stored, processed, or converted—not merely whether the diffraction pattern appears unchanged.

Six Distinctions Required for an Approval Decision

Terms That Must Be Separated	Correct Interpretation	Approval Risk When Confused
HPLC area purity vs assay	Area purity describes the relative chromatographic response of included peaks; assay estimates target-compound content under a defined quantitative method	High chromatographic purity may conceal water, solvent, inorganic matter, or another stoichiometric form
Typical value vs specification limit	A typical value describes representative or historical behavior; a specification limit defines a release requirement	A typical KF or TGA result may be mistaken for batch-level control
Dry basis vs as-is or wet basis	Dry-basis content applies a defined drying or volatile-content correction; as-is content describes the material in its received condition	Corrected assay may overstate the amount of target compound actually charged from a variable hydrate or solvate
Detection vs quantitation	A signal may be detected without being reliably quantified; “not detected” does not prove absolute absence	A trace solvent or minor phase may be treated as absent without sufficient method capability
Test result vs professional inference	A measured value is an observation; assigning it to a hydrate, solvate, or trapped solvent is an interpretation	An unsupported assignment may be repeated as though it were a directly measured fact
Document presence vs evidence sufficiency	Several analytical reports are useful only when their batches, methods, references, and sample histories can be connected	A complete-looking document package may still fail to prove the intended commercial form

Area Purity Cannot Replace Form-Corrected Assay

A hydrate or solvate may show high HPLC area purity because water and many volatile components do not appear as conventional organic impurity peaks.

The material may still contain less target compound per unit mass than the chromatographic percentage suggests.

The detailed distinction between HPLC area purity and assay should therefore be applied before using a purity result for reaction-equivalent calculations or commercial specification comparison.

Dry Basis Must Be Defined, Not Assumed

A dry-basis assay reports content after applying a defined drying procedure or volatile-content correction. What is removed from the calculation depends on the method and should not automatically be assumed to represent water alone.

For an intended hydrate, dry-basis reporting may be useful for understanding the underlying organic component. It may be unsuitable as the only basis for process charging when the delivered material is weighed as received.

For an intended anhydrous material, a corrected result can also conceal commercially relevant variation if actual water or solvent differs across batches.

The specification, assay calculation, and downstream dosing basis should refer to the same material state.

What Evidence Is Needed at Each Approval Stage?

A successful laboratory experiment does not prove that the same solid form will be delivered during pilot or commercial supply.

Decision Stage	Evidence the Stage May Support	Conditions Requiring a Hold
Exploratory sample	Preliminary reaction screening, analytical-method development, or observation of form sensitivity	Form designation is unconfirmed, sample history is unknown, or only one form-related test is available
Formal sample qualification	Same-batch DSC, TGA, XRPD, KF, assay, and relevant solvent data interpreted against an intended form	Results cannot be reconciled, the XRPD reference is undefined, or the reporting basis does not match intended use
Pilot production	Assessment of whether material behavior remains acceptable under representative charging, drying, handling, and process conditions	Pilot material differs from the qualified sample in crystallization, drying, milling, packaging, or storage history
Bulk procurement	Evaluation of representative commercial lots, routine release controls, packaging protection, and batch consistency	Commercial production does not preserve the qualified form or form-related tests are only informational rather than release controls

Exploratory Samples Can Be Used Without Being Formally Approved

An incompletely characterized sample may still be useful for:

preliminary reaction-feasibility work;
analytical-method development;
observation of moisture sensitivity;
initial drying or handling experiments.

Its status should remain exploratory.

The result should not be used to establish final reaction equivalents, incoming specifications, commercial packaging, or batch-release criteria unless the relevant form and content evidence has been resolved.

Pilot Production Tests Process Sensitivity, Not Just Sample Performance

Pilot work should test whether the material remains suitable under conditions closer to actual operation.

Relevant differences may include:

time between container opening and charging;
room-humidity exposure;
powder transfer and milling;
pre-drying;
charging temperature;
larger batch hold times;
storage after partial container use.

A pilot batch may perform differently even when its HPLC area purity matches the laboratory sample. The cause may be water level, solvent retention, phase conversion, or differences in physical handling rather than a conventional organic impurity.

Bulk Approval Requires Representative Commercial Evidence

Bulk procurement should not rely only on a specially prepared development sample or one selected production batch.

A commercial approval package should clarify:

the intended supplied form;
the process conditions that create and preserve that form;
which form-related attributes are tested on each batch;
whether the release methods match those used during qualification;
how packaging and storage protect the material state;
whether redrying or reprocessing can produce another phase;
whether commercial lots remain comparable after normal transport and handling.

Where form changes can alter dosing or processing, a high purity result cannot compensate for missing commercial-form control.

Why Matching Laboratory Results Still May Not Prove Commercial Form Control

Quality discussions often focus on whether DSC, TGA, XRPD, and KF each meet an expected result. The overlooked question is whether the results describe a reproducible material state rather than a favorable laboratory snapshot.

Even same-batch data are not automatically comparable when aliquots were:

collected at different times;
stored in different containers;
exposed to different humidity;
ground before one test but not another;
pre-dried for one method;
tested after different holding periods.

A clean analytical package can therefore support an internally consistent interpretation while failing to represent the material that reaches pilot or commercial production.

The more important industry question is not whether a hydrate or solvate can be identified once. It is whether the manufacturing, drying, sampling, packaging, and release system repeatedly delivers the same form within a usable processing window.

This changes the approval logic.

A buyer should not ask only:

Do the results match the expected form?

The stronger question is:

Would the same conclusion still be reached after scale-up, routine packaging, transport, storage, and normal production handling?

Where the answer is unknown, additional curves from a specially controlled sample may add less value than representative commercial-batch data with documented sample history.

Solid-form control is ultimately evidence of process capability. Analytical agreement supports that conclusion only when the tested material is representative of the material that will actually be purchased and used.

Questions That Can Change the Approval Decision

Question	Why It Matters	Warning Sign
What exact hydrate, solvate, or anhydrous form is intended for routine supply?	Establishes the target material state	The form appears only in the product name and is not linked to batch evidence
Were DSC, TGA, XRPD, KF, assay, and solvent testing performed on the same batch?	Determines whether the results can be cross-interpreted	Typical curves from unrelated batches are combined with one current COA
How were the aliquots stored and conditioned before testing?	Reveals whether the tests represent comparable sample histories	Sample exposure, grinding, or pre-drying is undocumented
What reference supports the XRPD conformity decision?	Defines what phase the batch is being compared with	The report says only “conforms”
What evidence supports the DSC and TGA event assignments?	Separates measured events from proposed explanations	Mass loss or endotherms are labelled without water, solvent, or phase evidence
How was KF suitability or water recovery assessed for this material?	Determines whether the result reflects total accessible water	Poor dissolution or extraction behavior is not addressed
Is a nonaqueous solvent expected from the process or proposed solid form?	Identifies a component that KF cannot measure	TGA is used as the only solvent result
Is assay reported as-is, on a dry basis, or using another correction?	Aligns the result with actual material charging	The COA and purchasing specification use different reporting bases
Are form-related values specifications or typical information?	Shows whether each commercial batch is controlled	Only representative data are available
Are sample, pilot, and commercial batches produced using comparable crystallization and drying conditions?	Tests whether early approval can be extended to scale	The qualified sample came from a different or specially adjusted process
Which form-related tests are performed for routine release?	Defines the actual commercial control strategy	XRPD or thermal data are supplied only during development
Can packaging, storage, or redrying change the material form?	Identifies post-release conversion risk	No assessment exists despite moisture- or solvent-sensitive behavior

The Approval Rule

DSC, TGA, XRPD, and KF can support approval only when they answer complementary parts of the same material-state question.

A defensible conclusion requires:

batch-specific rather than purely typical data;
a defined target form and XRPD reference;
water and solvent results appropriate to the proposed composition;
thermal-event assignments supported by other evidence;
assay reported on a basis consistent with material charging;
comparable sample preparation and exposure histories;
representative pilot and commercial-batch evidence;
routine release controls capable of detecting meaningful form variation.

Where one result conflicts with the others, the discrepancy should be treated as unresolved quality information—not averaged, ignored, or explained through assumption.

Buyers evaluating a form-sensitive intermediate can submit a material-specific RFQ to ChemicalCell with the intended solid form, reporting basis, sample stage, commercial quantity, and required batch evidence.